

INTEGRATED BIOPHARMA INC

Form 5

August 14, 2008

FORM 5**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**Check this box if
no longer subject
to Section 16.Form 4 or Form
5 obligations
may continue.See Instruction
1(b).Form 3 Holdings
Reported

Form 4

Transactions

Reported

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0362Expires: January 31,
2005Estimated average
burden hours per
response... 1.0

1. Name and Address of Reporting Person *

KAY ROBERT

2. Issuer Name and Ticker or Trading
SymbolINTEGRATED BIOPHARMA INC
[INBP]5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Statement of Issuer's Fiscal Year Ended
(Month/Day/Year)
06/30/2008☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

225 LONG AVE

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Reporting

(check applicable line)

HILLSIDE, NJ 07205

☒ Form Filed by One Reporting Person
☐ Form Filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	02/07/2007	Â	A4 ⁽¹⁾	34,000 A	\$ 0 (1) 1,030,962 (2)	D	Â
Common Stock	08/12/2008	Â	C4 ⁽³⁾	200,000 A	\$ 1,030,962 (2) 0.85	D	Â

Reminder: Report on a separate line for each class of
securities beneficially owned directly or indirectly.**Persons who respond to the collection of information
contained in this form are not required to respond unless
the form displays a currently valid OMB control number.**SEC 2270
(9-02)

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 5

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Underlying Se (Instr. 3 and 4)
					(A) (D)	Date Exercisable Expiration Date Date	Title
Stock Options	\$ 6.8	02/07/2007	Â	A4 ⁽⁴⁾	16,000 Â	Â ⁽⁴⁾ 12/20/2007	Common Stock
Stock Options	\$ 0.85	08/12/2008	Â	C4 ⁽³⁾	Â 200,000	02/04/2003 02/04/2013	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
KAY ROBERT 225 LONG AVE HILLSIDE,Â NJÂ 07205	Â X Â Â Â

Signatures

/s/ ROBERT
KAY 08/14/2008

 **Signature of
Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- On February 7, 2007, the Reporting Person was granted 34,000 Restricted Stock Units as compensation for serving as a director of the
- (1) Issuer. Each Restricted Stock Unit consists of a right to the issuance of one share of common stock, par value \$.002 ("Common Stock"). The Restricted Stock Units are subject to a three-year vesting period.
- (2) Represents the amount of securities beneficially owned by the Reporting Person as of the date hereof.
- (3) On August 5, 2008, the Reporting Person exercised 200,000 options to purchase common stock of the Issuer. The options were originally granted to the Reporting Person for his service as a director of the Issuer.
- On February 7, 2007, the Reporting Person was granted a stock option to purchase 16,000 shares of Common Stock at an exercise price
- (4) of \$6.80 per share as compensation for serving as a director of the Issuer. These stock options are subject to a three-year vesting period, with an initial annual vesting date of December 20, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.